After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the two companies said on ...

Tempus AI's growth and partnerships make it an attractive investment. See why TEM stock is a solid Buy due to its ...

In the judge's view, the changes to the 'tick' device and the font, strapline and colours in the logo variants did not alter ...